Adams Respiratory Therapeutics Inc
Adams Respiratory Therapeutics — Investor Presentation (April 2007)
60 slides from Adams Respiratory Therapeutics's investor presentation, Apr 4, 2007

Slide 1: New OTC Products Review
Bob Casale Chief Operating Officer New OTC Products Review April 4, 2007

Slide 2: Safe Harbor
Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. ("Adams") as of the date of this presentation and are subject to uncertainty and changes in circu

Slide 3: Total CCAS Category Dollar Sales Trend 2002-2006
Total CCAS Category Dollar Sales Trend ($ MM) 2002-2006 4 Year CAGR 4 Year CAGR Category +8.4% Cough Syrup/Sore Throat +1.5% CAS Liquids/ Powders +0.2% CAS Tablets/ Packets +13% Source: Information Resources, Inc. (IRI), U.S. Food/Drug/Mass (FDMx) , 2002-2006. 2,159 2,715 2,602 2,972 2,986 Category

Slide 4: Total CCAS Category Growth Brands - Dollar Sales Change
$223 $10 $72 $305 All other Brands Delsym Mucinex Total CCAS Growth Brands Of the $305MM in CCAS growth brands this past year, Adams contributed $82MM- more than a quarter of the total. Source: IRI, U.S. FDMx, 52 weeks ended 2/25/07. Dollar Sales Chg VYA ($MM) Total CCAS Category Growth Brands - Dol

Slide 5: CCAS Category Major Brands Performance
CCAS Category Major Brands Performance $ % Chg VYA $ Share Chg Vs. VYA +62.1 11.0 +3.5 +50.8 10.2 +2.7 +1.1 6.8 -0.6 +0.2 6.7 -0.7 +12.0 6.1 0.1 -4.7 5.0 -0.8 +20.2 4.7 +0.3 -5.9 3.9 -0.2 +23.8 3.7 +0.4 +10.6 2.9 +0.0 61.8 2.3 +0.7 Source: IRI, U.S. FDMx, 12 weeks ended 2/25/07. $ Sales (MM) (r) (r)

Slide 6: CCAS Brands Productivity Rank - $ Sales per SKU
CCAS Brands Top 10 Productivity Rank - $ Sales per SKU Top 10 Productivity Rank - $ Sales per SKU Top 10 Productivity Rank - $ Sales per SKU Avg # SKU's carried Dollar Sales Rank 9 2 5 7 3 14 4 12 14 3 15 5 15 6 33 1 11 9 21 4 Source: IRI, U.S. FDMx, 12 weeks ended 2/25/07 Note: Avg # SKU's is for t

Slide 7: Adams is a major player in the total CCAS category
Source: IRI U.S. FDMx, 52 weeks ended 7/2/06 and projection for 52 weeks ending 7/1/07. Mucinex(r) Mucinex(r) DM Mucinex(r) D Mucinex(r) Children's Liquids Mucinex(r) Children's Mini-Melts Delsym(r) 3.7 3.2 1.1 0.4 0.6 10.7% total 0.7 1.7 4.9 2.1 0.6 6.6% total FY 2006 FY 2007 Projected Adams is a m

Slide 8: Fiscal 2007 New Products
Fiscal 2007 New Products Fiscal 2007 Fiscal 2006

Slide 9: Mucinex Core Equity
Mucinex Core Equity Mucinex = Mucus Out

Slide 10: Loyal Consumer Base
Loyal Consumer Base Of the consumers who use Mucinex... ~90% intend to buy it again ~30% try more than one type of Mucinex ~70% actually plan their purchase ~50% would rather make an additional trip to another store if their store did not have Mucinex Source: Proprietary on-line research conducted 1

Slide 11: Mucinex Advertising Awareness High
Mucinex Advertising Awareness High 51% 38% Advertising Awareness Mucinex ranks # 2; only Nyquil(r) higher at 55%. Ahead of Claritin(r) (44%) - despite 2x Mucinex spending during cough/cold season Surpasses both Robitussin(r) and Tylenol(r) - 33% Far exceeds level of other new brands - Airborne(r) (2

Slide 12: Ad Awareness the Key Driver of Overall Awareness
Ad Awareness the Key Driver of Overall awareness of Mucinex 69% 78% Brand Awareness Mucinex brand awareness of 78% is exceptional when compared to that of more established brands: Claritin(r) - 87%; Tylenol(r)/Robitussin(r)/Nyquil(r) - 97-99% Far exceeds the level achieved by other new brands: Airbo

Slide 13: Strong Professional Following
1. Pharmacy Times, 2007 OTC Survey of Pharmacists Recommendations conducted 10/06. 2. Proprietary Physician Tracking Study conducted 12/06. Strong Professional Following In a few short years, Mucinex has... Become #1 pharmacist recommended adult expectorant1 Achieved the highest satisfaction rate am

Slide 14: Mucinex Patient Satisfaction and Symptom Relief
90%+ of patients were pleased with Mucinex were pleased with Mucinex were pleased with Mucinex One week of treatment with Mucinex significantly improved all mucus-related symptoms Symptom Relief 100% 0 100% # of Patients COUGH EXCESS MUCUS NASAL CONGESTION THICK MUCUS CHEST CONGESTION 75.1 68.7 67.8

Slide 15: Consumer/Professional: Working Together to Build Trial & Conversion
Consumer Advertising Professional Detailing Generates Consumer Awareness Generates Professional Recommendations Trial Purchase Satisfied Consumer Consumer/Professional: Working Together to Build Trial & Conversion

Slide 16: Top Three Influencers of Mucinex Trial
Top Three Influencers of Mucinex Trial Recommendations by healthcare professionals 49% Friend/family recommendation 31% TV advertising 28% Source: Proprietary consumer tracking study conducted 12/06.

Slide 17: Mucinex Adult Products Today
Mucinex Adult Products Today 600 mg. guaifenesin-based 12 hour tablets Leading position in cough, cold and sinus segments Highly productive franchise

Slide 18: Introducing...The Next Major Addition to the Mucinex Franchise
Introducing...The Next Major Addition to the Mucinex Franchise Addition to the Mucinex Franchise Addition to the Mucinex Franchise

Slide 19: Mucinex Adult Products Where We Are Going
Address consumer that demands maximum strength treatment options Expand franchise across any Upper Respiratory segment, Rx or OTC, that delivers consumer value through innovation and stays true to "mucus out" equity Mucinex Adult Products Where We Are Going OTC Rx

Slide 20: Market Research Confirms Need for Maximum Strength Product
Market Research Confirms Need for Maximum Strength Product Key Findings* Majority of respondents were very interested in buying Maximum Strength Mucinex Majority prefer one tablet dose of Maximum Strength Mucinex Research also indicates that Mucinex franchise revenue should increase significantly wi

Slide 21: Maximum Strength Mucinex Strengthens the Mucinex Franchise
Maximum Strength Mucinex Strengthens the Mucinex Franchise Source: Maximum Strength Mucinex Discrete Choice Study, 3/07. Definitely / Probably "would buy" 58% 83% Total Category Users Mucinex Users Strong interest in Maximum Strength Mucinex among both non-users and current users Based upon key attr

Slide 22: Mirrors Existing Consumer Behavior
Mirrors Existing Consumer Behavior Preferred Mucinex Dosage for Mucinex and Non-Mucinex Users Source: Maximum Strength Mucinex Discrete Choice Study, 3/07. Source: Maximum Strength Mucinex Discrete Choice Study, 3/07. 63% of current Mucinex users take only one tablet per dose Majority of consumers w

Slide 23: 46% of Volume Comes From Competitive Brands
46% of the Volume for Maximum Strength Mucinex Comes From Competitive Brands 54% of the volume for Maximum Strength should come from current Mucinex products Most vulnerable competitors include: Vicks Nyquil(r)/Dayquil(r), 11%; Robitussin(r), 9%; Tylenol(r), 6% Source: Maximum Strength Mucinex Discr

Slide 24: Strong Potential for Maximum Strength
Strong Potential for Maximum Strength In Year 1, Maximum Strength Mucinex is projected to achieve between $50MM and $70MM in consumption Approximately 40% of Maximum Strength Mucinex dollars expected to be incremental Total Adult Mucinex franchise is expected to grow in excess of 20% Source: Maximum

Slide 25: Maximum Strength Potential
Maximum Strength Potential Research indicates that over time, Maximum Strength Mucinex may represent 60% of Mucinex franchise sales Assumes: Full distribution Continued support Acceptability of tablet size Source: Maximum Strength Mucinex Discrete Choice Study, 3/07.

Slide 26: Marketing Maximum Strength Mucinex
Marketing Maximum Strength Mucinex Dedicated TV commercial Focused Professional efforts targeted to doctors and pharmacists

Slide 27: Children's Mucinex Line
Children's Mucinex Line

Slide 28: Children's Mucinex and Delsym expanded the category
Children's Mucinex and Delsym expanded the category Children's CCAS Category Major Brands Performance Major Brands Performance Major Brands Performance $ % VYA $ Share Chg VYA +61.6 19.5 +3.4 +22.4 19.3 -1.7 +29.0 12.1 +0.4 n/a 8.3 8.3 +22.9 6.9 -0.6 -9.3 6.0 -2.8 +63.9 5.8 +1.1 -43.0 4.7 -6.3 +16.4

Slide 29: Children's CCAS Brands Productivity Rank
Children's CCAS Brands Productivity Rank - $ Sales per SKU Avg # SKU's carried Dollar Sales Rank 6.1 1 1.5 7 3.3 4 5.0 3 10.1 2 3.8 5 3.7 8 5.0 6 1.6 10 2.4 9 $ Sales per SKU (MM) Source: IRI, U.S. FDMx, 12 weeks ending 2/25/07. (r) (r) (r) (r) (r) (r) (r) (r)

Slide 30: Children's Mucinex Products Today
Children's Mucinex Products Today Immediate-release guaifenesin-based line Innovative form addressing consumer needs Highly productive line poised for a top place within segment

Slide 31: Introducing...The New Additions to the Children's Mucinex Line
Introducing...The New Additions to the Children's Mucinex Line

Slide 32: Two New Indications
Two New Indications Adding New Indications to the Children's Line 100 mg guaifenesin/ 5 mg dextromethorphan HBr Orange Creme flavor Congestion and cough "Cough" for Mini-Melts 100 mg guaifenesin/ 2.5 mg phenylephrine/5 ml Mixed Berry flavor Nasal congestion & Cough "Cold" for Liquids

Slide 33: Children's Mucinex Products Where We Are Going
Parents' product of choice for cough/cold relief for their children Technology-based point of difference Address convenience, compliance and efficacy needs Future introductions may not be limited to monographed OTC products Children's Mucinex Products Where We Are Going

Slide 34: Children's Mucinex Meets Consumer Needs
Children's Mucinex Meets Consumer Needs Mini-Melt Cough and Liquid Cold formulations Cough is viewed as most disruptive symptom by parents* "Good taste" and "easy to take" are critical to compliance according to both moms and pediatricians* Cold indication represents multi-symptom relief Children's

Slide 35: Children's Mucinex Marketing Support
Children's Mucinex Marketing Support Dedicated TV commercial Focused Professional efforts targeted to pediatricians

Slide 36: Mucinex equity travels to a new market segment
Mucinex equity travels to a new market segment

Slide 37: Strong Equity Relevant To Consumers
Strong Equity Relevant To Consumers Established brand equity "Mucinex In, Mucus out.(tm)" Successful launch in children's segment indicates opportunity to extend Mucinex brand name All 4 SKUs rank among the top twenty-five; outselling established competitive liquids1 1IRI, FDMx, 4 weeks ended 2/25/0

Slide 38: Introducing...
Introducing... Seis seca rele iin emery Sosubce tes a _| a fs Concentrated Vapor Technology to ea J RESEIRATOR’ P\ Ow 38

Slide 39: Mucinex Nasal Sprays Unique Benefits
Mucinex Nasal Sprays Unique Benefits Full Force Effective nasal decongestant "Sensory signal" lets consumer know it is working "12 Hour Concentrated Vapor Technology" Moisture Smart Effective nasal decongestant Specially formulated to soothe irritated nasal membranes "12 Hour Membrane Hydration Tech

Slide 40: Mucinex Nasal Sprays will compete in a $370MM OTC category
Mucinex Nasal Sprays will compete in a $370MM OTC category Nearly a 50/50 split between medicated and non-medicated segments. IRI, FDMx 52 Wks Ended 12/31/06 $ Sales (MM) % Chg VYA Total Nasal Category $370 +7 Non-Medicated Sprays/Drops/Inhalers 194 +12 Medicated Sprays/Drops 177 +4 Mucinex Nasal Sp

Slide 41: Mucinex Should Build Nasal Spray Category
Proprietary research indicates that 64% of current Mucinex adult users who do not use other nasal sprays intend to purchase Mucinex Nasal Spray Importantly, these users will add this new product to their treatment regimen Mucinex Should Build Nasal Spray Category Source: Proprietary research conduct

Slide 42: Mucinex Will Also Capture Existing Nasal Spray Consumers
Mucinex Will Also Capture Existing Nasal Spray Consumers 57% of current nasal spray users also expressed intent to purchase Mucinex Nasal Spray Current Afrin(r) users potentially the largest source Mucinex adds value with 50% more product per unit Higher Retail Revenue Higher Mucinex Retail Ring Sou

Slide 43: Mucinex Nasal Sprays Market Opportunity
Mucinex Nasal Sprays Market Opportunity Expands Mucinex franchise into additional respiratory segment High percentage of cough /cold category sufferers also use nasal sprays Year 1 projected to achieve 4% - 5% dollar share of nasal sprays market. Leading Medicated Nasal Spray Brands 2006 Dollar Shar

Slide 44: Mucinex Nasal Sprays Marketing Support
Mucinex Nasal Sprays Marketing Support Dedicated TV commercial Consumer incentives to purchase both nasal spray and base Mucinex Professional efforts targeted to pharmacists

Slide 45: Mr. Mucus Highlights
Mr. Mucus Highlights "Here's Mucus" - Mucinex DM "Wrap" - Mucinex SE "Painter" - Children's Mucinex Mini-Melts

Slide 46: Coming Soon: The New Adventures of Mr. Mucus
Coming Soon: The New Adventures of Mr. Mucus

Slide 47: I, RESPIRATORY
I, RESPIRATORY THERAPEUTICS” (OI

Slide 48: Delsym Core Equity
Delsym Core Equity Delsym = 12 hour Cough Relief

Slide 49: Delsym Provides Unique Benefits
Delsym Provides Unique Benefits The first and only OTC cough liquid that suppresses cough for 12 hours 4 hours longer than leading competitor Patented extended-release technology Great-tasting flavor

Slide 50: Delsym acquisition and objectives
Delsym Adams acquired Delsym in June 2006 from UCB to: Increase critical mass within respiratory market and develop a strategic foothold in OTC cough syrup segment Leverage our core competency: synergistic consumer and professional marketing Gain access to an additional proprietary delivery technolo

Slide 51: Delsym Consumption Reached New High
Source: IRI U.S. FDMx, 52 weeks ended 2/25/07. *4 weeks ended 12/31/06. Adams Acquired Delsym(r) Professional Promotion Began Consumer Advertising Began Delsym Consumption Reached New High +70% VYA Achieved all-time consumption high of 18.9% at peak* ahead of Robitussin(r) DM 101

Slide 52: Delsym
Delsym SUPPRESSANT Delsym COUGH SUPPRESSANT Deisym COUGH SUPPRESSANT 12.3 HOUR Cough Reliet neisym y i RESPIRATORY Is 52

Slide 53: Delsym Users Highly Loyal to Brand
Over 50% of Delsym users did not consider purchasing another brand to treat their cough 90% of purchasers plan to buy Delsym again Nearly 60% of users treated their cough with Delsym exclusively Delsym Users Highly Loyal to Brand Source: Proprietary on-line research conducted 12/06. High consumer sa

Slide 54: Delsym Where We Are Now
Delsym Where We Are Now Fastest-growing cough syrup brand Highly productive franchise Single-flavor focused for Adults and Children's

Slide 55: Delsym Where We Are Going
Delsym Where We Are Going Building awareness and trial (significant upside potential) Franchise expansion that delivers against the core benefit of 12 hour relief Improved shelf presence

Slide 56: New Delsym Grape Flavor
New Delsym Grape Flavor Grape line extension Flavor appeals to both children and adults Grape is #1 flavor in Children's segment with 39% of retail market* Available in both Adult 3 oz. and Children 3 oz. Same active ingredient and dosing as orange flavor * IRI, U.S. FDMx, 52 weeks ended 2/25/07.

Slide 57: Delsym Grape Should Attract New Users
Delsym Grape Should Attract New Users New grape variety provides greater choice to consumers for whom flavor is a trial motivator Fills an important flavor gap in the franchise Total Delsym consumption is expected to grow 15% to 20% in FY08

Slide 58: Delsym Marketing Support
Delsym Marketing Support Dedicated TV commercial

Slide 59: Fiscal 2007 New Products
Fiscal 2007 New Products Fiscal 2007 Fiscal 2006

Slide 60: Expansion Accelerates in FY08
Expansion Accelerates in FY08 Fiscal 2008
Source: SEC EDGAR · 8-K filed Apr 4, 2007
More decks from Adams Respiratory Therapeutics Inc
Q1 FY2008 Earnings Presentation12 slides · Nov 8, 2007
Q3 FY2007 Earnings Presentation21 slides · May 10, 2007
Technical Presentation (April 2007)25 slides · Apr 4, 2007
Investor Presentation (April 2007)10 slides · Apr 4, 2007
Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conferen (February 2007)21 slides · Feb 8, 2007
Q2 FY2007 Earnings Presentation28 slides · Feb 7, 2007